☰

Brian G. Van Ness - Publications

Affiliations: 
Molecular, Cellular, Developmental Biology and Genetics University of Minnesota, Twin Cities, Minneapolis, MN 
Area:
Genetics, Bioinformatics Biology, Epidemiology
Tree Info Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Baughn LB, Jessen E, Sharma N, Tang H, Smadbeck JB, Long MD, Pearce K, Smith M, Dasari S, Sachs Z, Linden MA, Cook J, Keith Stewart A, Chesi M, Mitra A, ... ... Van Ness B, et al. Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma. Blood Cancer Journal. 13: 84. PMID 37217482 DOI: 10.1038/s41408-023-00851-5  0.498
2022 Kumar H, Mazumder S, Sharma N, Chakravarti S, Long MD, Meurice N, Petit J, Liu S, Chesi M, Sanyal S, Stewart AK, Kumar S, Bergsagel L, Rajkumar SV, Baughn LB, ... Van Ness BG, et al. Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. Frontiers in Oncology. 12: 842200. PMID 35646666 DOI: 10.3389/fonc.2022.842200  0.328
2022 Kumar H, Mazumder S, Chakravarti S, Sharma N, Mukherjee UK, Kumar S, Baughn LB, Van Ness BG, Mitra AK. secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics. Blood Cancer Journal. 12: 39. PMID 35264575 DOI: 10.1038/s41408-022-00636-2  0.303
2020 Mitra AK, Kumar H, Ramakrishnan V, Chen L, Baughn L, Kumar S, Rajkumar SV, Van Ness BG. In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma. Blood Cancer Journal. 10: 78. PMID 32724061 DOI: 10.1038/S41408-020-00344-9  0.308
2016 Baughn LB, Sachs Z, Noble-Orcutt KE, Mitra A, Van Ness BG, Linden MA. Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry. Leukemia & Lymphoma. 1-10. PMID 27981867 DOI: 10.1080/10428194.2016.1266621  0.532
2016 Mitra AK, Stessman HA, Schaefer RJ, Wang W, Myers CL, Van Ness BG, Beiraghi S. Fine-Mapping of 18q21.1 Locus Identifies Single Nucleotide Polymorphisms Associated with Nonsyndromic Cleft Lip with or without Cleft Palate. Frontiers in Genetics. 7: 88. PMID 27242896 DOI: 10.3389/fgene.2016.00088  0.647
2014 Fall DJ, Stessman H, Patel SS, Sachs Z, Van Ness BG, Baughn LB, Linden MA. Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma. Journal of Cancer. 5: 720-7. PMID 25368671 DOI: 10.7150/Jca.9864  0.714
2014 Stessman HA, Lulla A, Xia T, Mitra A, Harding T, Mansoor A, Myers CL, Van Ness BG, Dolloff NG. High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma. Leukemia. 28: 2263-7. PMID 25005244 DOI: 10.1038/leu.2014.214  0.656
2014 Stessman HA, Mansoor A, Linden MA, Van Ness B, Baughn LB. Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency. Leukemia & Lymphoma. 55: 220-2. PMID 23734619 DOI: 10.3109/10428194.2013.797575  0.676
2013 Stessman HA, Mansoor A, Zhan F, Linden MA, Van Ness B, Baughn LB. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. Plos One. 8: e77608. PMID 24204892 DOI: 10.1371/Journal.Pone.0077608  0.722
2013 Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Molecular Cancer Therapeutics. 12: 1140-50. PMID 23536725 DOI: 10.1158/1535-7163.Mct-12-1151  0.723
2012 Fang G, Haznadar M, Wang W, Yu H, Steinbach M, Church TR, Oetting WS, Van Ness B, Kumar V. High-order SNP combinations associated with complex diseases: efficient discovery, statistical power and functional interactions. Plos One. 7: e33531. PMID 22536319 DOI: 10.1371/Journal.Pone.0033531  0.697
2012 Linden MA, Kirchhof N, Carlson CS, Van Ness BG. Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia. Experimental Hematology. 40: 216-27. PMID 22120021 DOI: 10.1016/J.Exphem.2011.11.006  0.507
2010 Church TR, Haznadar M, Geisser MS, Anderson KE, Caporaso NE, Le C, Abdullah SB, Hecht SS, Oken MM, Van Ness B. Interaction of CYP1B1, cigarette-smoke carcinogen metabolism, and lung cancer risk. International Journal of Molecular Epidemiology and Genetics. 1: 295-309. PMID 21532841  0.678
2008 Van Ness B, Ramos C, Haznadar M, Hoering A, Haessler J, Crowley J, Jacobus S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, et al. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. Bmc Medicine. 6: 26. PMID 18778477 DOI: 10.1186/1741-7015-6-26  0.698
2007 Morgan KJ, Rowley MA, Wiesner SM, Hasz DE, Van Ness B, Largaespada DA. The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells. Leukemia Research. 31: 1107-13. PMID 17222906 DOI: 10.1016/J.Leukres.2006.11.022  0.716
2005 Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene. 24: 6269-80. PMID 16007202 DOI: 10.1038/Sj.Onc.1208771  0.724
2004 Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD, Janz S. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. The Journal of Clinical Investigation. 113: 1763-73. PMID 15199411 DOI: 10.1172/Jci20369  0.635
2003 Linden M, Kirchhof N, Carlson C, Van Ness B. Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood. 103: 2779-86. PMID 14656874 DOI: 10.1182/Blood-2003-10-3399  0.492
2003 Croonquist PA, Linden MA, Zhao F, Van Ness BG. Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood. 102: 2581-92. PMID 12791645 DOI: 10.1182/Blood-2003-04-1227  0.727
Show low-probability matches.